Physician profile
Shivani Sood
NPI 1356500532
$7,771.83
in general payments reported to CMS, 2019-2025
37 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $441 · 2021: $1,003 · 2022: $1,126 · 2023: $860 · 2024: $929 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,820.54 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $948.37 | 2019-2025 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $784.82 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Allergan, INC. | $533.63 | 2019 | |
| Phathom Pharmaceuticals, INC. | $494.71 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $401.71 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $337.79 | 2019-2024 | |
| Gilead Sciences, INC. | $289.06 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $234.93 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $213.64 | 2019-2024 | Linzess |
| Celgene Corporation | $184.23 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $153.94 | 2025 | Rezdiffra |
| Qol Medical, LLC | $114.78 | 2019-2025 | Sucraid |
| E.R. Squibb & Sons, L.L.C. | $111.56 | 2021 | |
| Lilly USA, LLC | $104.30 | 2024-2025 | Omvoh, Zepbound |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $98.49 | 2019-2020 | |
| Ardelyx, INC. | $97.76 | 2022-2025 | Ibsrela |
| Concordia Pharmaceuticals INC. | $91.76 | 2019 | |
| Merck Sharp & Dohme LLC | $84.53 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $76.79 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $73.20 | 2023-2025 | Dupixent |
| Ucb, INC. | $65.37 | 2019 | |
| Medtronic, INC. | $65.25 | 2024 | Barrx |
| Ferring Pharmaceuticals INC. | $58.14 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $57.84 | 2024 | Bylvay |
| Aimmune Therapeutics, INC. | $55.59 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $30.27 | 2019 | |
| Fresenius Kabi USA, LLC | $28.29 | 2023 | |
| Alnylam Pharmaceuticals INC. | $26.94 | 2023 | Givlaari |
| Viiv Healthcare Company | $23.92 | 2024 | |
| Amgen INC. | $22.39 | 2025 | Uplizna |
| Exact Sciences Corporation | $21.83 | 2024 | Cologuard Collection Kit |
| Alfasigma USA, INC. | $20.19 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.00 | 2025 | Rexulti |
| Shire North American Group INC | $15.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.20 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.